Q-omics provides the consensus-scored SRRM5 profile across patient tissues and cancer cell-line models. SRRM5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SRRM5 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SRRM5 RNA expression shows 19,408 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where SRRM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRRM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRRM5 survival associations across molecular data types. SRRM5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRRM5 RNA expression–survival associations across cancer types. High SRRM5 expression shows unfavorable associations in KIRC, KICH, ACC, LGG and LIHC, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SRRM5 RNA expression.
This table summarizes SRRM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SRRM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRRM5 shows higher tumor expression in COAD, LUSC, LIHC, HNSC, STAD and BLCA. The COAD box plot shows higher SRRM5 RNA expression in tumor versus normal tissue (log2 FC = +0.483, t-test p < 0.001).
This table shows molecular features associated with SRRM5 in patient tissues and cancer cell lines. In patient samples, SRRM5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SRRM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
